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Background: The most commonly used pharmacologic therapies for bipolar depression are mood 
stabilizers, atypical antipsychotics, and antidepressants. This paper reviews common side effects 
associated with these medications and provides recommendations for managing adverse medication 
effects in clinical practice.
Methods: Narrative review based on literature searches of Medline and evidence-based treatment 
guidelines for agents that have been approved by the US Food and Drug Administration and/or are 
commonly used to treat bipolar depression.
Results: Side effects of bipolar depression pharmacotherapies are common and vary by medication, 
with weight gain, metabolic dysregulation, sedation/somnolence, and akathisia among those observed 
most frequently. These adverse events (weight gain and sedation/somnolence, in particular) negatively 
affect treatment adherence in patients with bipolar disorder. Furthermore, endocrine and metabolic 
comorbidities, weight gain, and obesity may reduce the likelihood of positive clinical responses to 
pharmacologic therapies. Clinicians may consider switching patients to bipolar depression medication(s) 
with a lower propensity for sedation or adverse metabolic effects. Lifestyle modification (e.g., dietary 
changes, exercise) is an important component in the treatment of weight gain/obesity, dyslipidemia, 
hypertension, and hyperglycemia; in addition, a wide range of medications are available as therapeutic 
options for patients in whom non-pharmacologic management strategies are insufficient. The use of 
adjunctive medication may also reduce treatment-related sedation and somnolence.
Limitations: The selection of relevant studies from the literature search relied primarily on the author’s 
expertise in the area of bipolar depression and knowledge of the issues addressed.
Conclusions: Successful treatment of bipolar depression extends beyond managing mood symptoms to 
also monitoring adverse medication events and managing associated medical disorders.
© 2014 Elsevier B.V. All rights reserved.
Review
Managing the side effects associated with commonly used treatments for 
bipolar depression
David E. Kempa,*
a Department of Psychiatry, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, USA
Contents lists available at ScienceDirect
Journal of Affective Disorders
j our na l  homepage: www.e lsev ie r.com/ loca te / jad
* Corresponding author at: Case Western Reserve University, 10524 Euclid 
Avenue, 12th Floor, Cleveland, OH 44106, USA. Tel.: +1 216 844 2865;  
fax: +1 216 844 2875.
 E-mail address: kemp.david@gmail.com (D.E. Kemp).
 
0165-0327/© 2014 Elsevier B.V. All rights reserved.
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S35
2. Methods  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S35
3. Atypical antipsychotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S35
3.1 Quetiapine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S35
3.2 Olanzapine-fluoxetine combination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S36
3.3 Lurasidone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S36
4. Mood stabilizers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S36
5. Antidepressants  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S37
5.1 Selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S37
5.2 Other antidepressants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S37
6. Managing adverse effects of pharmacotherapy for bipolar depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S37
6.1 Weight and metabolic issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S38
6.2 Sedation/somnolence  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S39
6.3 Cardiovascular issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S39
6.4 Other adverse effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S40
7. Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S40
8. Conclusion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S40
 D.E. Kemp / Journal of Affective Disorders 169 S1 (2014) S34–S44 S35
1. Introduction
As reviewed by Shefali Miller, MD, and colleagues in this 
supplement, there is substantial evidence demonstrating that 
bipolar disorder, particularly during the more pervasive depressive 
phase, is associated with significant disability (Kupka et al., 
2007; Sanchez-Moreno et al., 2009). This functional impairment 
is further compounded by the substantial number of medical 
comorbidities that are seen in bipolar disorder patients (Kemp et 
al., 2013). In particular, it has been well documented that there 
is a relationship between bipolar disorder and certain metabolic 
abnormalities, including obesity, dyslipidemia, and insulin 
resistance (Kemp and Fan, 2012).
These interrelated symptoms — abdominal obesity, elevated 
triglyceride levels, decreased high-density lipoprotein cholesterol 
levels, hypertension, and hyperglycemia — are collectively known 
as metabolic syndrome and are associated with increased risk for 
the development of cardiovascular disease and type 2 diabetes 
(Grundy et al., 2004). The increased prevalence of metabolic 
syndrome and obesity in patients with bipolar disorder, as high 
as twice the rate observed in the general population, has been 
theorized to involve lifestyle factors (e.g., poor diet, lack of 
exercise, smoking), lack of proper healthcare resources, common 
underlying neurobiological processes, and adverse effects of 
commonly used treatments (Calkin et al., 2013; Correll et al., 2010; 
Ford et al., 2002; McIntyre et al., 2012; Salvi et al., 2008; Sicras et 
al., 2008; Vancampfort et al., 2013; Vuksan-Cusa et al., 2010).
Two of the three treatments that are currently approved for 
treating bipolar depression (olanzapine [in combination with 
fluoxetine, OFC] and quetiapine) are among the atypical anti-
psychotics known to cause significant weight gain and metabolic 
dysregulation, as well as other tolerability issues, such as sedation/
somnolence (Frye, 2011). Lurasidone, the most recent (third) 
atypical antipsychotic approved to treat bipolar depression, 
appears to have a lower propensity for weight gain and metabolic 
adverse effects than the two older agents; however, akathisia has 
been commonly reported (Latuda® [lurasidone hydrochloride] 
tablets, for oral use, 2013; Kane et al., 2009). Potentially serious 
safety concerns are also associated with traditional mood 
stabilizers, including lithium-related toxicity, valproate-associated 
reproductive abnormalities, and rare but serious lamotrigine-
induced rash (Frye, 2011).
The limited number of approved treatments, the safety 
and tolerability profiles of the available medications, and the 
medical comorbidities and profile of risk factors unique to each 
individual patient all make the management of bipolar depression 
a challenging task. The objective of this article is to provide an 
overview of the tolerability and safety issues associated with 
bipolar depression medications and to discuss strategies for 
effectively managing them. By increasing their familiarity with 
the tolerability and safety profiles of these drugs, clinicians 
may be able to more efficiently identify the most appropriate 
treatment regimens for individual patients, provide proactive 
management strategies to help improve adherence and treatment 
outcomes, and reduce the potential for serious long-term medical 
complications and comorbidities.
2. Methods
Evidence-based treatment guidelines for bipolar disorder were 
reviewed to identify agents that have been approved by the US 
Food and Drug Administration (FDA) and/or are commonly used 
for bipolar depression. Searches of the PubMed database were 
then conducted for clinical trials and other articles on the use of 
these agents to treat patients with bipolar depression. In addition, 
prescribing information for these medications was consulted, and 
ongoing trials of products in development were identified using 
ClinicalTrials.gov.
3. Atypical antipsychotics
Antipsychotic agents were developed for the treatment of 
schizophrenia and now are also widely used for mood disorders, 
including bipolar disorder and treatment-resistant depression. 
Most of the 10 atypical antipsychotics originally indicated for the 
treatment of schizophrenia have demonstrated efficacy in manic or 
mixed episodes associated with bipolar disorder, and 3 (quetiapine 
monotherapy, OFC, and lurasidone monotherapy or adjunctive 
to mood stabilizers) are approved to treat depressive episodes 
associated with bipolar disorder (Latuda® [lurasidone hydrochloride] 
tablets, for oral use, 2013; Seroquel® [quetiapine fumarate] tablets, 
2013; Symbyax® [olanzapine and fluoxetine hydrochloride] capsule 
for oral use, 2012; Yatham et al., 2013). Common areas of concern 
across atypical antipsychotics include the potential for treatment-
emergent weight gain and metabolic dysregulation, sedation, and 
extrapyramidal symptoms (Henderson, 2007; Henderson et al., 
2006; McIntyre and Konarski, 2005; Newcomer, 2007).
3.1 Quetiapine
Quetiapine at a daily dose of 300 mg or 600 mg has consistently 
demonstrated efficacy for treating acute episodes of bipolar 
depression (Calabrese et al., 2005; McElroy et al., 2010; Suppes 
et al., 2010; Thase et al., 2006; Young et al., 2010). Sedation/
somnolence has been shown to develop in approximately half 
of patients enrolled in short-term studies of bipolar depression 
(Calabrese et al., 2005; McElroy et al., 2010; Suppes et al., 2010; 
Thase et al., 2006; Young et al., 2010) and is the adverse event that 
most often led to premature treatment discontinuation (Calabrese 
et al., 2005; Suppes et al., 2010; Thase et al., 2006).
Quetiapine is also associated with weight gain (albeit to a 
lesser extent than OFC) in patients with bipolar depression. 
Mean weight change was 1–2 kg during short-term treatment 
and 0–1 kg during long-term treatment (Calabrese et al., 2005; 
McElroy et al., 2010; Suppes et al., 2010; Thase et al., 2006; Young 
et al., 2010; Young et al., 2012). Clinically significant weight gain 
(≥7% of baseline weight) occurred in 4–11% of bipolar depression 
patients treated with quetiapine, compared with 1–4% of patients 
who received placebo (Table 1) (Calabrese et al., 2005; McElroy et 
al., 2010; Suppes et al., 2010; Thase et al., 2006; Young et al., 2010; 
Young et al., 2012).
However, mean changes in lipid and glucose levels during 
treatment with quetiapine were generally small and similar 
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to those in the placebo group (Calabrese et al., 2005; McElroy 
et al., 2010; Suppes et al., 2010; Thase et al., 2006; Young et al., 
2010; Young et al., 2012). In short-term studies, the proportion of 
patients with clinically relevant changes in metabolic parameters 
was generally similar for quetiapine and placebo; during longer-
term treatment, clinically relevant shifts occurred more often 
with quetiapine (particularly 600 mg/d) (Table 1).
3.2 Olanzapine-fluoxetine combination
OFC has demonstrated efficacy in short-term and long-term 
studies of bipolar depression, but is associated with significant 
weight gain and metabolic dysregulation (Table 1) (Brown et al., 
2009; Brown et al., 2006; Corya et al., 2006; Tohen et al., 2003b). 
The proportion of patients with potentially clinically significant 
weight gain (≥7%) during short-term (6–8 weeks) treatment of 
acute bipolar depression with OFC was 19–23%, compared with 
0.3% with placebo and 0% with lamotrigine (Brown et al., 2006; 
Tohen et al., 2003b). During a 6-month extension study, rates of 
clinically significant weight gain were 33.8% with OFC and 2.1% 
with lamotrigine (p<0.001) (Brown et al., 2009).
In addition to notably high rates of potentially clinically 
significant weight gain, OFC is also associated with elevations in 
total cholesterol, triglyceride, and glucose levels (Brown et al., 
2009; Brown et al., 2006; Tohen et al., 2003b).
OFC is also associated with treatment-emergent sedation/
somnolence, occurring in 19–21% of patients compared with 12.5% 
of patients receiving placebo and 8–9% of patients treated with 
lamotrigine (Brown et al., 2009; Brown et al., 2006; Tohen et al., 
2003b).
A significant proportion of OFC–treated bipolar depression 
patients have been shown to experience clinically relevant 
orthostatic hypotension (7.3%) and increases in supine systolic 
blood pressure (4.9%) that were more common than with olanza-
pine monotherapy (1.4% and 0.6%; both p<0.01) or placebo (1.4% 
and 1.7%; p=0.008 and p=0.10) during 8 weeks of treatment (Tohen 
et al., 2003b).
3.3 Lurasidone
Lurasidone was recently approved by the FDA for acute 
bipolar I depression as monotherapy (Loebel et al., 2014a) and as 
adjunctive therapy with lithium or valproate (Loebel et al., 2014b). 
The efficacy of lurasidone for acute bipolar I depression was 
established at daily doses of 20–120 mg/d in two 6-week, placebo-
controlled studies — one of lurasidone monotherapy (Program to 
Evaluate Antidepressant Impact of Lurasidone [PREVAIL] 2; Loebel 
et al., 2014a) and one of lurasidone as adjunctive treatment with 
lithium or valproate (PREVAIL1; Loebel et al., 2014b). Adverse 
event data are available from these studies and from an additional 
adjunctive treatment study in bipolar depression patients who 
were non-responders to treatment with lithium or valproate 
alone (Lurasidone HCI – A 6-week phase 3 study of patients with 
bipolar I depression [PREVAIL3], NCT01284517, 2012). The most 
commonly observed adverse events with lurasidone in patients 
with acute bipolar I depression were nausea (14%), akathisia 
(9–11%), extrapyramidal symptoms (7–14%), and somnolence/
sedation (11%) (Latuda® [lurasidone hydrochloride] tablets, 
(2013). These adverse events were somewhat more common 
at higher (80–120 mg/d) than at lower (20–60 mg/d) doses of 
lurasidone monotherapy: nausea, 17% vs. 10%; akathisia, 11% vs. 
8%; extrapyramidal symptoms, 9% vs. 5%; and somnolence, 14% 
vs. 7% (2013). Overall, the incidence of somnolence/sedation with 
lurasidone is comparable to that observed with other low-sedating 
atypical antipsychotics (aripiprazole and ziprasidone) (Kane 
and Sharif, 2008). Lurasidone demonstrated a low propensity 
for weight gain in studies of bipolar depression, with minimal 
changes in lipid and glucose levels (2013).
4. Mood stabilizers
The key adverse events associated with mood stabilizers vary 
by medication. Lamotrigine is not associated with significant 
sedating effects; rather, it has been described as having an 
activating profile (Ketter et al., 2003). Sedation/somnolence has 
been noted in a substantial proportion of patients treated with 
valproate (Bowden et al., 2000; Ghaemi et al., 2007), however, 
and lithium has been shown to cause sedation/somnolence and 
cognitive impairment (Calabrese et al., 2003; Suppes et al., 2008).
Short-term lithium therapy does not generally lead to 
substantial treatment-emergent weight gain (Young et al., 2010); 
however, lithium was associated with a mean weight increase of 
1–4 kg during 1 year of maintenance treatment for bipolar disorder 
(McIntyre et al., 2011; Sachs et al., 2006), and mean weight gain 
was greatest (6 kg) in patients who were already obese (Bowden 
et al., 2006). Valproate is associated with weight gain in patients 
with epilepsy (Fagiolini and Chengappa, 2007), and significant 
weight gain has also been observed in maintenance studies of 
bipolar disorder (Bowden et al., 2000; Tohen et al., 2003a). One 
long-term study found that, in valproate-treated patients with 
Table 1
Proportion of patients* with clinically relevant changes† during short-term (8-12 weeks) and long-term (48-52 weeks) treatment with quetiapine and 
olanzapine-fluoxetine combination (OFC) for bipolar depression.
 Weight Gain Glucose (Fasting)  Glucose (Fasting)  Triglycerides Triglycerides Total Cholesterol 
 ≥7% ≥126 mg/dL ≥200 mg/dL ≥200 mg/dL >500 mg/dL ≥240 mg/dL
 Short- Long- Short- Long- Short- Long- Short- Long- Short- Long- Short- Long- 
 term  term  term  term  term term term  term  term term term  term
Quetiapine 300 mg/d 3.9–9.0% 6.4% 2.6–5.6% 10.5% NA NA 9.9–14.2% 5.6% NA NA 4.1–8.1% 14.1%
Quetiapine 600 mg/d 8.3–11.3% 9.4% 3.0–4.3% 7.3% NA NA 14.7–14.8% 14.7% NA NA 8.2–8.9% 12.7%
Placebo 0.8–4.1% 4.0% 1.4–4.3% 5.9% NA NA 9.1–13.0% 6.9% NA NA 3.6–10.1% 6.5%
OFC 22.0% 66.0% NA NA 4.4% 5.4% NA NA 9.8% NA 20.9% NA
Placebo 1.8% NA NA NA 0.5% NA NA NA NA NA 4.9% NA
*Patients receiving OFC had a diagnosis of bipolar depression or treatment-refractory depression.
†As measured at the final assessment in short-term studies of quetiapine (Calabrese et al., 2005; McElroy et al., 2010; Suppes et al., 2010; Thase et al., 2006; Young 
et al., 2010) or any study visit in the long-term study of quetiapine (Young et al., 2012) and based on random glucose levels and nonfasting lipid levels for OFC.
NA = not available.
Data from Calabrese, J.R., et al., 2005, Am. J. Psychiatry 162 (7), 1351-1360; McElroy, S.L., et al., 2010, J. Clin. Psychiatry 71 (2), 163-174; Suppes, T., et al., 2010, 
J. Affect. Disord 121 (1-2). 106-115; Symbyax® (olanzapine and fluoxetine hydrochloride) capsule for oral use [package insert], Indianapolis, IN: Eli Lilly and 
Company, 2012; Thase, M.E., et al., 2006, J. Clin. Psychopharmacol 26 (6), 600-609; Young, A.H., et al., 2010, J. Clin. Psychiatry 71 (2) 150-162; Young, A.H., et al., 
2014, World J. Biol. Psychiatry 15 (2), 96–112.
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bipolar disorder, weight gain was more likely to occur at serum 
levels above 125 mcg/mL (Bowden et al., 2000). Lamotrigine 
generally causes little, if any, weight gain in patients with acute 
bipolar depression (Bowden et al., 2006; Calabrese et al., 2003; 
Calabrese et al., 1999; Suppes et al., 2008).
Valproate use in patients with bipolar disorder has been 
associated with the development of polycystic ovary syndrome, 
a reproductive-endocrine abnormality that is frequently charac-
terized by insulin resistance (Joffe et al., 2006a; Joffe et al., 
2006b).
Because of its narrow therapeutic window, the potentially 
toxic effects of lithium are an essential treatment consideration 
(Severus et al., 2008). The adverse effects of greatest concern 
involve the central nervous system, kidneys, and thyroid 
(Calabrese and Woyshville, 1995; Oliveira et al., 2010). According 
to a recent meta-analysis, lithium was associated with a reduced 
glomerular filtration rate (–6.2 mL/min); a 15% reduction in 
maximum urinary concentrating ability; hypothyroidism (odds 
ratio: 5.8 [95% confidence interval 2.0–16.7]); and increased 
thyroid stimulating hormone (+4.0 iU/mL), parathyroid hormone 
(+7.3 pg/mL), and blood calcium (+0.09 mmol/L) (McKnight et al., 
2012). However, the observed risk of end-stage renal failure was 
relatively small (0.5%).
The product label for lamotrigine includes warnings about 
the occurrence of serious, life-threatening rashes and aseptic 
meningitis (Lamictal® [lamotrigine] tablets, 2011). Lamotrigine-
associated rash was evaluated in an analysis of 12 clinical trials 
conducted in patients with mood disorders; 8.3% of patients 
receiving lamotrigine experienced a benign rash, compared with 
a rate of 6.4% for patients taking placebo (Calabrese et al., 2002). 
In this review, one case of serious rash (in a patient receiving 
placebo) and 1 case of nonserious Stevens-Johnson syndrome were 
reported (Calabrese et al., 2002). Postmarketing surveillance from 
1995-2009 identified 40 cases of meningitis in patients receiving 
lamotrigine, 15 of which demonstrated a positive rechallenge 
(Simms et al., 2012).
Mood stabilizers have been shown to have significant 
teratogenic effects. A concerning association between maternal 
lithium treatment during pregnancy and Ebstein’s anomaly (a 
congenital prolapse of the tricuspid valve into the right ventricle) 
was reported in the 1970s, based on data from a registry of 
voluntarily submitted cases; however, subsequent epidemiological 
studies found a much lower risk (Cohen et al., 1994). A literature 
review of prospective and retrospective studies assessing the 
effects of valproate in pregnancy concluded that major teratogenic 
effects occurred in approximately 10% of offspring born to patients 
with epilepsy who were taking valproate, a rate that was 3 times 
greater than that seen in offspring of non–valproate-treated 
patients (Ornoy, 2009). The congenital anomalies associated 
with valproate included heart defects; cleft lip and palate; and 
those affecting the urinary tract, limbs, and brain, including 
neural tube defects (Ornoy, 2009). Data from a North American 
pregnancy registry indicate a significantly increased risk of cleft 
lip/cleft palate in infants who were exposed to lamotrigine during 
the first trimester in utero (Holmes et al., 2008). Taken together, 
the above profile of side effects has led clinicians to exercise 
considerable caution when considering use of valproate in women 
of reproductive age.
As a class, anticonvulsants carry a warning for increased risk 
of suicidal thoughts or behavior. Although patients and family 
members should be informed of the potential for suicidality 
and emergence of depression or any unusual thoughts and 
behaviors during anticonvulsant treatment, it is important not 
to over-emphasize this risk, as refusing initiation or prematurely 
stopping treatment may also result in serious harm to the patient 
(Fountoulakis et al., 2012).
5. Antidepressants
The key adverse events associated with antidepressant use vary 
by class of antidepressant and, sometimes, by medication within 
each class. Fluoxetine combined with olanzapine is FDA-approved 
for acute bipolar I depression. All other use of antidepressants for 
bipolar depression is not FDA-approved. Treatment guidelines 
recommend against antidepressant monotherapy in bipolar 
depression (Yatham et al., 2013). Moreover, a recent International 
Society for Bipolar Disorders task force report recommended 
avoiding antidepressant monotherapy in bipolar I depression 
and in bipolar II depression with two or more concomitant core 
manic symptoms (Pacchiarotti et al., 2013). Accordingly, much 
of the data on adverse effects of antidepressants in patients 
with bipolar disorder are confounded by concomitant use of 
atypical antipsychotic agents and/or mood stabilizers. Below, 
unless otherwise specified, antidepressant side effects refer to 
monotherapy in patients with unipolar major depressive disorder.
5.1 Selective serotonin reuptake inhibitors and serotonin and 
norepinephrine reuptake inhibitors
During acute phase therapy, the various selective serotonin 
reuptake inhibitors (SSRIs) and serotonin and norepinephrine 
reuptake inhibitors (SNRIs) do not generally cause significant 
treatment-emergent weight gain (Hasnain et al., 2012; Serretti 
and Mandelli, 2010). However, the SSRI paroxetine is associated 
with significant increase in weight during long-term maintenance 
treatment (Hasnain et al., 2012; Serretti and Mandelli, 2010).
Sexual dysfunction is a widely recognized adverse effect of SSRI 
use; prevalence appears to be comparable between SSRIs and the 
SNRI venlafaxine and somewhat lower with the SNRI duloxetine 
(Papakostas, 2008). Antidepressants acting on the noradrenergic 
system (i.e., SNRIs) are associated with significantly greater 
increases in blood pressure and heart rate than those observed 
with selective serotonergic antidepressants (Bielski et al., 2004; 
Goldstein et al., 2002; Sir et al., 2005).
5.2 Other antidepressants
Mirtazapine is a mixed-mechanism antidepressant that is 
associated with significant weight gain during short-term and 
maintenance therapy (Serretti and Mandelli, 2010), and with 
relatively high rates of somnolence and fatigue (Papakostas, 
2008). Sexual dysfunction occurs less frequently with mirtazapine 
compared with SSRIs (Bet et al., 2013; Watanabe et al., 2010).
Bupropion, a norepinephrine-dopamine reuptake inhibitor 
(Thase et al., 2005), has been shown to reduce body weight 
during both acute and maintenance therapy (Serretti and 
Mandelli, 2010), has minimal propensity for sedation/somnolence 
(Thase et al., 2005), and is associated with relatively low rates 
of sexual dysfunction (Papakostas, 2008; Serretti and Chiesa, 
2009). Synergistic effects on weight loss have been observed 
in overweight/obese patients when bupropion is combined 
with naltrexone (Apovian et al., 2013; Greenway et al., 2009; 
Greenway et al., 2010). Seizures are of concern with bupropion 
but occur rarely at recommended doses (0.1% for patients taking 
the sustained-release formulation and 0.4% patients for patients 
taking immediate-release bupropion) (Fava et al., 2005).
6. Managing adverse effects of pharmacotherapy for bipolar 
depression
The safe and effective treatment of bipolar depression 
requires collaboration between medical care providers and 
patients, including routine discussions of therapeutic and adverse 
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medication effects and shared decision-making regarding changes 
in the therapeutic regimen. Monitoring of adverse effects is an 
essential component of therapeutic management. Suggested 
guidelines for routine and medication-specific monitoring of 
patients with bipolar depression are provided in Table 2.
6.1 Weight and metabolic issues
Given the prevalence and detrimental impact of weight gain 
and metabolic dysregulation, treatment should extend beyond 
managing mood symptoms to also include other outcomes, such 
as monitoring and controlling dyslipidemia and hyperglycemia, 
and encouraging healthy lifestyle changes including weight loss, 
smoking cessation, and stress management (Birkenaes et al., 
2007; Birkenaes et al., 2006; Brietzke et al., 2011).
For patients experiencing clinically relevant, treatment-
emergent weight gain, a switch in treatment regimen may be 
considered (McIntyre et al., 2012). Compared with valproate 
or lithium, lamotrigine is a mood stabilizer option that is less 
likely to cause weight gain (Fagiolini and Chengappa, 2007). For 
patients taking quetiapine or OFC, lurasidone is an alternative 
antipsychotic with a relatively favorable weight and metabolic 
profile. Ziprasidone is another atypical antipsychotic with low 
propensity for weight gain (Kemp et al., 2012b); however, it has 
failed to demonstrate efficacy in the treatment of acute bipolar 
depression (Lombardo et al., 2012; Sachs et al., 2011). Like 
ziprasidone, aripiprazole is approved for the acute treatment of 
manic or mixed episodes associated with bipolar I disorder and 
for maintenance therapy (Abilify® [aripiprazole] tablets, 2012; 
Geodon® [ziprasidone HCl] capsules, 2012), but has two negative 
studies for bipolar depression (Thase et al., 2008). Also, although 
aripiprazole has a generally favorable metabolic profile (Kemp et 
al., 2010), it has been associated with considerable weight gain in 
some patients with bipolar disorder (Keck, Jr. et al., 2007; Keck, Jr. 
et al., 2006).
Behavioral and lifestyle modification, which involve initiating 
a basic exercise routine and making dietary changes, are 
important components of treatment (McElroy and Keck, Jr., 2012; 
McIntyre et al., 2012). In a study of patients who were mentally 
ill and overweight, a behavioral weight loss regimen resulted in 
a significantly greater reduction in mean weight over 18 months 
compared with that observed in the control group (Daumit et al., 
2013).
Table 3 summarizes available pharmacological treatments 
for obesity that may be necessary for patients who continue 
to experience weight gain or do not experience any weight 
Table 2
Routine safety assessments for all patients with bipolar disorder and additional medication-specific guidelines for agents commonly used for bipolar depression 
or as maintenance treatment for bipolar disorder.
Initial health assessment for all patients with bipolar disorder
•	 Medical	history,	including	family	history	of	cardiovascular	disease	and	diabetes	 •	 Pregnancy	and	contraception	(for	women	of	child-bearing	potential)
•	 Weight,	BMI,	and	waist	circumference	 •	 Blood	pressure
•	 Complete	blood	count	 •	 Liver	function
•	 Renal	function	 •	 Thyroid	function
•	 Fasting	lipid	profile	 •	 Fasting	blood	glucose
•	 Smoking	and	alcohol	use
Additional medication-specific monitoring for commonly used agents
Agent Start of Treatment Monthly Every 3 Months Every 6 Months Other
AAPs	 	 	 •	 Weight*	 •	 Blood	pressure†	 	 	 •	 ECG	and	prolactin	level,	
	 	 	 •	 BMI*	 •	 Fasting	plasma	glucose†    as clinically appropriate
	 	 	 •	 Waist	circumference*	 •	 Fasting	lipid	profile‡    based on patient risk 
          factors and safety  
          profile of the specific  
          agent
Lithium	 •	 Calcium	 	 	 •	 Renal	function	 •	 Thyroid	function||
	 •	 Serum	level	of	medication§		 	 	 •	 Calcium||
	 	 	 	 	 	 	 •	Weight||
	 	 	 	 	 	 	 •	 Serum	level	of	medication
Valproate	 •	Hematological	and		 	 	 •	Weight† •	 Complete	blood	count|| •	 Blood	pressure,	lipid
	 	 hepatic	history	 	 	 	 	 •	 Liver	function||  profile, and fasting
	 •	 Serum	level	of	medication§		 	 	 •	 Serum	level	of		 	 glucose	in	patients	with
        medication  risk factors 
	 	 	 	 	 	 	 	 	 •	 Bone	density	in	patients	 
          with risk factors 
	 	 	 	 	 	 	 	 	 •	Monitor	for	menstrual	 
          irregularities, especially  
          during the first year
Lamotrigine	 	 	 	 	 	 	 	 	 •	Monitor	for	rash,	 
          especially during the  
          first 8 weeks
*Monthly for the first 3 months of treatment, then every 3 months.
†Every 3 months for the first year, then annually.
‡At 3 months and then annually.
§When initiating treatment, establish two consecutive serum levels in the therapeutic range. Obtain serum levels 5 days after dose titration for lithium and 3-5 
days after dose titration for valproate.
||At 6 months and then annually.
AAPs = atypical antipsychotics; BMI = body mass index; ECG = electrocardiogram.
Adapted from treatment guidelines (National Institute for Health and Clinical Excellence, 2006; American Diabetes Association et al., 2004, Diabetes Care, 36 
(Suppl 1), S67–S74; Goodwin, 2009, J. Psychopharmacol, 23 (4), 346–388; Ng et al., 2009, Bipolar Disord, 11 (6), 559–595; Yatham et al., 2005, Bipolar Disord., 7 
(Suppl 3), 5–69) and other evidence-based recommendations (Calabrese et al., 2002, J. Clin. Psychiatry, 63 (11), 1012–1019; Haddad et al., 2009, Expert Opin. Drug 
Metab. Toxicol, 5 (5), 539–551; Joffe et al., 2006b, Biol. Psychiatry, 59 (11), 1078–1086; Malhi et al., 2012, Bipolar Disord., 14 (Suppl 2), 1–21).
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loss after implementing lifestyle modifications (e.g., diet and 
exercise) and/or changing treatment regimens (Tsigos et al., 
2008). Pharmacotherapy (combined with lifestyle modifications) 
is recommended for patients who are overweight and have a 
complicating weight-related comorbidity (e.g., dyslipidemia, 
hypertension, diabetes) or are obese, regardless of the presence of 
a comorbid medical condition (Tsigos et al., 2008).
Metformin is the most extensively studied pharmacotherapy 
for patients experiencing weight gain during treatment with 
atypical antipsychotics and has been shown in a meta-analysis to 
produce a mean weight loss of 3 kg over 12-16 weeks of follow-up 
(Ehret et al., 2010). As a result, metformin is recommended as a 
second-line treatment option following behavioral interventions 
(McIntyre et al., 2012).
Orlistat, an FDA–approved agent for weight reduction (Xenical® 
[orlistat] capsules for oral use, 2012), has been shown to reduce 
body weight in patients experiencing olanzapine- and clozapine-
related weight gain (Tchoukhine et al., 2011), and has also been 
recommended as a second-line option for use in patients with 
bipolar disorder (McIntyre et al., 2012). In addition to reducing 
antipsychotic-associated weight gain and metabolic dysfunction 
(Narula et al., 2010), topiramate has produced significant weight 
loss when used adjunctively with mood stabilizers in patients 
with bipolar disorder (Chengappa et al., 2006; McIntyre et al., 
2002). However, adverse effects of topiramate on cognitive 
functioning may limit its utility (Goldberg and Chengappa, 2009). 
Lorcaserin, a novel selective serotonin 5-HT2c receptor agonist, was 
recently approved by the FDA for the treatment of obesity but has 
not yet been evaluated in psychiatric patients (Fidler et al., 2011; 
Goldenberg, 2012).
The judicious use of psychostimulants may provide increased 
control of eating behaviors and weight reduction. The combination 
of phentermine (a sympathomimetic amine) and topiramate was 
recently FDA-approved for chronic weight management in adult 
patients with an initial body mass index (BMI) of ≥30 kg/m2, or 
BMI ≥27 kg/m2 in the presence of at least one weight-related 
comorbid condition (e.g., hypertension, dyslipidemia, type 2 
diabetes) (Qsymia® [phentermine and topiramate extended-
release] capsules, for oral use, CIV, 2013). In addition, the 
psychostimulant lisdexamfetamine dimesylate has shown a dose-
dependent reduction in binge-eating episodes in patients with 
moderate or severe binge-eating disorder (Jancin, 2013).
In patients with prediabetic hyperglycemia, dietary changes and 
exercise may prevent or delay progression to diabetes (American 
Diabetes Association, 2004). Studies of antihyperglycemic agents 
for patients with bipolar disorder are lacking; therefore, treatment 
recommendations have been taken from general guidelines 
(American Diabetes Association, 2012; Calkin et al., 2013). 
Pharmacological treatments include metformin for milder type 2 
diabetes and insulin for more severe type 2 diabetes and type 1 
diabetes, as recommended by the American Diabetes Association 
(American Diabetes Association, 2012). Other noninsulin therapies 
for type 2 diabetes are listed in Table 4. Preliminary evidence 
suggests that concomitant administration of the peroxisome 
proliferator-activated receptor gamma agonist pioglitazone may 
help reduce depressive symptoms in addition to reversing insulin 
resistance (Kemp et al., 2012a; Kemp et al., 2014).
Because alterations in lipid homeostasis have been linked to 
increased body weight, lifestyle modification is recommended 
as first-line therapy for patients experiencing dyslipidemia 
during bipolar depression treatment (McIntyre et al., 2012). 
For patients not responding to this first-line treatment option, 
pharmacological treatments for dyslipidemia, such as statins, 
niacin, resins, and fibrates, may be used (Department of Veterans 
Affairs and Department of Defense, 2006; McIntyre et al., 2012).
6.2 Sedation/somnolence
For the substantial proportion of patients who do not develop 
a tolerance to the sedating effects of medication, sedation/
somnolence can have a markedly negative effect on quality of 
life, contributing to weight gain and cognitive dysfunction and 
impairing social and occupational functioning (Kane and Sharif, 
2008). To manage treatment-emergent sedation/somnolence, 
physicians may consider switching to a less-sedating medication, 
if possible. Potentially less-sedating antipsychotic agents include 
aripiprazole, lurasidone, or ziprasidone (2013; Kane and Sharif, 
2008; McIntyre and Konarski, 2005). Lamotrigine is thought to 
have a lower propensity for sedation/somnolence than valproate 
and a more benign cognitive profile than lithium or valproate 
(Malhi et al., 2012). However, the use of mood-stabilizing drugs 
that are somewhat sedating may be necessary in order to maintain 
adequate symptom control. Changing the dosing schedule of a 
sedating medication from morning to evening administration may 
alleviate the negative impact of somnolence and sedation on daily 
functioning (Miller, 2004; Muench and Hamer, 2010).
The use of adjunctive medication is another possible means of 
alleviating treatment-related sedation and somnolence, as well 
as the commonly observed hypersomnolence that is associated 
with bipolar depression. Stimulants (e.g., methylphenidate, 
amphetamine) are one option (Carlson et al., 2004; Dell’Osso and 
Ketter, 2013). Alternatively, the dopamine-reuptake inhibitors 
modafinil and armodafinil, which are approved for the treatment 
of excessive sleepiness associated with obstructive sleep apnea, 
narcolepsy, or shift work disorder (Nuvigil® [armodafinil] tablets 
[C-IV], 2013; Provigil® [modafinil] tablets [C-IV], 2010), may 
provide relief from somnolence/sedation and may also have 
an antidepressant effect in patients with bipolar depression 
(Calabrese et al., 2010; Frye et al., 2007). When employing these 
stimulant or stimulant-like interventions, caution is necessary to 
avoid mood destabilization.
6.3 Cardiovascular issues
The Dietary Approaches to Stop Hypertension (DASH) 
combination diet, which involves increased consumption of fruits, 
vegetables, and low-fat dairy products and decreased consumption 
of saturated fat and cholesterol, has been shown to significantly 
Table 3
Treatments for weight loss or mitigation of psychotropic-induced weight 
gain.
  Bipolar Other Psychiatric 
  Disorder Disorders*
Nonpharmacologic treatment
 Lifestyle modification,  1 1 
 including exercise, dietary  
 changes, and cognitive  
 interventions
Pharmacologic treatments
 Amantadine 2 1
 Liraglutide Not studied 3
 Metformin 2 1
 Modafinil Not studied 2
 Naltrexone/bupropion Not studied 3
 Nizatidine Not studied 1
 Orlistat Not studied 2
 Phentermine Not studied Not studied
 Topiramate 1 1
 Zonisamide 2 2
Surgical intervention
 Bariatric surgery 3 3
*Includes schizophrenia, schizoaffective disorder, or depressive disorders.
1 = at least two randomized controlled trials (RCTs) and/or a meta-analysis;  
2 = one RCT; 3 = open-label study/retrospective study/case-report.
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decrease blood pressure in relation to a control diet (Appel, 2009; 
Svetkey et al., 1999). Other lifestyle modifications that can reduce 
blood pressure include weight loss, decreasing sodium intake, and 
moderating alcohol consumption (Appel, 2009). Pharmacological 
treatment options for hypertension are listed in Table 4 (Appel, 
2009; Chengappa et al., 2006; Department of Veterans Affairs and 
Department of Defense, 2006; Fidler et al., 2011; Goldenberg, 2012; 
Gradman et al., 2011; McIntyre et al., 2012; McIntyre et al., 2002).
6.4 Other adverse effects
Although the rate of extrapyramidal symptoms is lower 
with atypical antipsychotics in comparison with conventional 
antipsychotic drugs, patients with bipolar disorder appear 
more vulnerable to the development of akathisia and other 
extrapyramidal symptoms than patients with schizophrenia 
(Gao et al., 2008). Akathisia is the most common form of 
extrapyramidal symptom and may improve with a beta blocker, 
such as propranolol, or a benzodiazepine. Anticholinergic agents 
are generally considered first-line treatments when Parkinsonian 
features or dystonias develop.
Prevention of the potentially toxic effects of lithium is 
dependent on therapeutic drug monitoring to determine whether 
lithium levels are below those known to cause toxic effects, yet 
high enough to produce a positive treatment effect (i.e., 0.4–
1.2 mmol/L) (Severus et al., 2008). To prevent the development 
of congenital anomalies associated with valproate use, women 
should use a reliable form of contraception, take the dietary 
supplement folate daily to reduce the risk of neural tube defects, 
and discontinue treatment if they plan to become pregnant (Ornoy, 
2009). Although hormonal contraceptives may also mitigate the 
risk of polycystic ovarian syndrome with valproate, their variable 
effects on mood indicate that caution is necessary when they are 
administered to women with bipolar disorder.
The risk of developing a lamotrigine-induced rash can be 
reduced by following a steady titration schedule. Calabrese et al. 
(2002) recommend initiating treatment with a lamotrigine dose 
of 25 mg/d during the first 2 weeks of treatment, then increasing 
the dose to 50 mg/d during weeks 3 and 4, followed by weekly 
increases of 50–100 mg/d as necessary until the desired degree of 
efficacy is reached (Calabrese et al., 2002). A rash occurring within 
the first 5 days of treatment initiation is not likely drug-related, 
whereas rash occurring after 5 days is more likely caused by 
lamotrigine (Calabrese et al., 2002). Rashes related to lamotrigine 
treatment that may portend particularly poor outcomes generally 
may be widespread, itchy, and tender; involve the neck and upper 
body, including the eyes and mouth; and are associated with 
other symptoms, such as fever or pharyngitis (Calabrese et al., 
2002). Patients who experience lamotrigine-related rash should 
discontinue treatment and be monitored for involvement of renal, 
hepatic, and hematological systems. These patients generally 
should not be rechallenged with lamotrigine; however, patients 
whose rash was not severe can be rechallenged if clinically 
warranted (i.e., if the potential risk for developing rash is less than 
the risk of the patient experiencing clinical worsening) (Lorberg 
et al., 2009).
7. Limitations
The selection of relevant studies from the literature search 
relied primarily on the author’s expertise in the area of bipolar 
depression and knowledge of the issues addressed. Randomized 
controlled clinical trials can have limited ability to detect harms 
that are rare or arise slowly.
8. Conclusion
The adverse events associated with commonly used treatments 
for bipolar depression vary by medication class, the particular 
agent used, and individual patient characteristics. Monitoring of 
patients with bipolar disorder should include routine assessments 
applicable to all patients and medication-specific evaluations 
based on the agent(s) prescribed. A collaborative effort of 
medical care providers and patients is important for the effective 
treatment of bipolar depression, including routine discussions of 
therapeutic and adverse medication effects and shared decision-
making regarding changes in the therapeutic regimen to achieve 
the optimal balance of efficacy and tolerability. Avoiding certain 
agents in patients with certain vulnerabilities (e.g., agents that 
cause weight gain in patients with baseline overweight or obesity) 
can help avoid side effects. Clinical and laboratory monitoring can 
permit earlier side effect detection and intervention. Adequate 
management of adverse effects, such as weight gain, metabolic 
dysregulation, and/or sedation, may require the use of adjunctive 
pharmacologic therapies in addition to behavioral management 
strategies. Maximizing medication safety and tolerability may 
improve patients’ adherence to treatment and enhance clinical 
outcomes, both for bipolar depression and general medical health.
Table 4
Nonpharmacologic and pharmacologic interventions for obesity and metabolic disturbance.
  Overweight/Obesity Dyslipidemia Hyperglycemia/Diabetes High Blood Pressure
Behavioral/lifestyle interventions
 Diet √ √ √ √
 Exercise √ √ √ √
 Smoking cessation    √
Pharmacologic interventions
  Metformin  Statins Metformin Angiotensin-converting 
  Orlistat  Niacin Sulfonylureas enzyme inhibitors 
  Topiramate  Fibrates Thiazolidinediones Angiotensin receptor 
  Lorcaserin   GLP-1 receptor agonists blockers 
  Phentermine and   DPP-4 inhibitors Beta-blockers 
  topiramate  Bromocriptine  Calcium channel 
    Insulin blockers
     Diuretics
GLP = glucagon-like peptide, DPP = dipeptidyl peptidase. Adapted from treatment guidelines and other evidence-based sources (American Diabetes Association, 
2012, Diabetes Care, 35 (Suppl 1), S11–S63; Appel, 2009, J. Clin. Hypertens., 11 (7), 358–368; Chengappa et al., 2006, J. Clin. Psychiatry, 67 (11), 1698–1706; 
Department of Veterans Affairs and Department of Defense, 2006, http://www.healthquality.va.gov/lipids/lip05_950_final2.pdf; Ferdinand, 2011, J. Clin. 
Hypertens. (Greenwich), 13 (9), 636–638; Fidler et al., 2011, J. Clin. Endocrinol. Metab., 96 (10), 3067–3077; Goldenberg, 2012, P. T., 37 (9), 499–502; Gradman et 
al., 2011, J. Clin. Hypertens. (Greenwich), 13 (3), 146–154; McIntyre et al., 2012, Ann. Clin. Psychiatry, 24 (1), 69–81; McIntyre et al., 2002, Bipolar Disord., 4 (3), 
207–213).
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